Pediatric dosing of rituximab revisited: Serum concentrations in opsoclonus-myoclonus syndrome

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 5, 2010, Pages e167-e172

  Pranzatelli, Michael R ^a,b   Tate, Elizabeth D ^a,b   Verhulst, Steven J ^b   Bertolone, Salvatore J ^c   Bhatla, Deepika ^d   Granger, Meaghan ^e   Lebowizc, Joseph ^f   Lockhart, Sharon K ^g   Wiley, Joseph M ^h  

^a National Pediatric Myoclonus Center   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Louisville School of Medicine   (United States)

^d SSM Cardinal Glennon Children's Medical Center   (United States)

^e The Jane and John Justin Neuroscience Center   (United States)

^f Children's Hospital of Austin   (United States)

^g MAIMONIDES MEDICAL CENTER   (United States)

^h SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

Anti B cell agent; Dancing eyes; IgM depletion; Kinsbourne syndrome; Neuroblastoma; Paraneoplastic syndrome; Rituximab pharmacokinetics

Indexed keywords

CORTICOTROPIN; DIPHENHYDRAMINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; PARACETAMOL; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; OPSOCLONUS MYOCLONUS SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DEPLETION; SCHOOL CHILD; ADOLESCENT; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; INFANT; METABOLISM; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADRENOCORTICOTROPIC HORMONE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN M; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INFANT; MALE; OPSOCLONUS-MYOCLONUS SYNDROME; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77955907835     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181cf0726     Document Type: Article

References (22)

1. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006; 6: 859-866.
2. Guilino LB, Bussel JB, Neufeld EJ. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr. 2007; 205: 338-344.
3. Pranzatelli MR, Travelstead AL, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology. 2004; 62: 1526-1532.
4. Pranzatelli MR, Travelstead AL, Tate ED, et al. CSF B cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord. 2004; 19: 770-777.
5. Cooper R, Khakoo Y, Matthay KK, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the children’s cancer group. Med Pediatr Oncol. 2001; 36: 623-629.
6. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol. 2006; 28: 585-593.
7. Bell J, Moran C, Blatt J. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer. 2008; 50: 370-371.
8. Corapcioglu F, Mutlu H, Kara B, et al. Response to rituximab and prednisone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma. Pediatr Hematol Oncol. 2008; 25: 756-761.
9. Leen WG, Weemaes CM, Verbeek MM, et al. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. Pediatr Neurol. 2008; 39: 213-217.
10. Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol. 1996; 19: 1-47.
11. Tate E, Pranzatelli MR, Harber J, et al. Pharmacokinetic and time-course study of rituximab in pediatric opsoclonus-myoclonus syndrome. Ann Neurol. 2007; 62(suppl 11): S113.
12. Pranzatelli MR, Huang YY, Tate E, et al. Monoaminergic effects of high dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Mov Disord. 1998; 13: 522-528.
13. Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit. 2000; 22: 295-301.
14. Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol. 2007; 62: 43-52.
15. Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. The Drug Monit. 2005; 27: 785-792.
16. Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkins lymphoma. Ann Oncol. 1998; 9: 995-1001.
17. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005; 45: 792-801.
18. Bennett CM, Bussel JB, Mueller BU, et al. Pharmacokinetics (PK) substudy of rituximab in a prospective clinical trial for pediatric chronic immune thrombocytopenic purpura (cITP). Blood (ASH Annual Meeting Abstracts). 2005; 106: Abstract 1243.
19. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. IMAJ. 2002; 4: 1006-1008.
20. Sawyer M, Ratain MJ. Body surface area as a determinant of pharmacokinetics and drug dosing. Investigational New Drugs. 2001; 19: 171-177.
21. Pranzatelli MR, Tate ED, Travelstead AL, et al. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus. J Clin Immunol. 2009 E pub ahead of print. PMID: 19838774.
22. Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler. 2009; 15: 189-192.